Munich Startup
rnhale

rnhale

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challeng...

Gründung2023
Business ModelSonstiges
BrancheLife Science

Über rnhale

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challenges of pulmonary RNA delivery, stability, deep lung deposition, and cellular uptake, our technology unlocks a more effective path for RNA-based therapies to reach their target. Our goal is to develop effective, locally-acting respiratory therapies that address disease at its molecular source. Our vision: to redefine the treatment of severe lung diseases.

Unsere Mission

We are bringing a new generation of efficient treatments to patients with COPD and asthma.

Unsere Vision

Redefining the therapy of severe lung diseases.

Mehr davon

Entdecke weitere Artikel, Startups und Events aus dem Ökosystem

Rnhale: Inhalierbare RNA für neue Therapien
Interviews

Rnhale: Inhalierbare RNA für neue Therapien

23.03.26
4 Min.
Deutscher Startup Monitor 2026 – Startup-Verband ruft GründerInnen zur Teilnahme auf
Ökosystem

Deutscher Startup Monitor 2026 – Startup-Verband ruft GründerInnen zur Teilnahme auf

07.08.26
2 Min.
Startups für City Demo Day 2026 gesucht
unkategorisiert

Startups für City Demo Day 2026 gesucht

07.08.26
3 Min.